Raymond James thinks Abbott Laboratories' (NYSE: ABT) 1Q results were solid and demonstrated the durable nature of ABT's portfolio, as three out of four business segments grew over 10% organically, with Nutrition growing 8% due to the recall.
The recall had a around $229 million impact on U.S. Nutrition sales. The analyst believes the variance between "mid and high single-digit" ex-CV guidance growth in 2022 is mainly due to the Nutrition recall.
